Macquarie Group
KYMR icon

Macquarie Group’s Kymera Therapeutics KYMR Stock Holding History

Macquarie Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-436
Closed -$11.5K – 2371
2022
Q2 		$9K Hold
436
– – ﹤0.01% 2458
2022
Q1 		$18K Hold
436
– – ﹤0.01% 2413
2021
Q4 		$28K Hold
436
– – ﹤0.01% 2323
2021
Q3 		$26K Hold
436
– – ﹤0.01% 2392
2021
Q2 		$21K Sell
436
-150
-26% -$6.51K ﹤0.01% 2353
2021
Q1 		$23K Buy
+586
New +$35.3K ﹤0.01% 2250

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Macquarie Group's KYMR Position: Q3 2022 in Review

Macquarie Group sold out of Kymera Therapeutics (KYMR) in Q3 2022, closing a stake of 436 shares — an estimated $11.5K sold.

Macquarie Group first reported a position in KYMR in Q1 2021 and held it in 6 quarters. The position peaked at $28K in Q4 2021. 127 funds tracked by Wall St. Rank hold KYMR as of Q3 2022.

  • Macquarie Group reported no remaining Kymera Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 436 Kymera Therapeutics shares in Q3 2022, an estimated $11.5K.
  • Macquarie Group first reported a position in Kymera Therapeutics in Q1 2021 and held it in 6 quarters.
  • Macquarie Group's Kymera Therapeutics position peaked at $28K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.